Cencora (NYSE:COR) Updates FY 2025 Earnings Guidance

Key Points

• Cencora (NYSE:COR) has updated its FY 2025 earnings guidance, projecting an EPS of $15.850-$16.000, slightly above the consensus estimate of $15.810.
• The company is forecasting revenue of $320.3 billion, which is lower than the consensus revenue estimate of $321.6 billion.
• Despite the earnings forecast, Cencora's shares fell 1.8% to $278.68, with notable insider selling occurring recently.

Cencora (NYSE:COR - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 15.850-16.000 for the period, compared to the consensus EPS estimate of 15.810. The company issued revenue guidance of $320.3 billion-$320.3 billion, compared to the consensus revenue estimate of $321.6 billion.

Cencora Stock Performance

Shares of NYSE COR traded up $7.06 during midday trading on Friday, hitting $285.46. 1,106,201 shares of the company's stock were exchanged, compared to its average volume of 1,099,116. The company has a quick ratio of 0.52, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora has a 12 month low of $218.65 and a 12 month high of $309.35. The company's 50 day moving average price is $292.51 and its 200 day moving average price is $277.58. The firm has a market capitalization of $55.33 billion, a PE ratio of 29.37, a price-to-earnings-growth ratio of 1.36 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%. The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 EPS. As a group, analysts predict that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, August 15th will be paid a $0.55 dividend. The ex-dividend date is Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.8%. Cencora's payout ratio is 22.63%.

Wall Street Analyst Weigh In

COR has been the subject of several recent research reports. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, Citigroup lifted their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $309.83.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the transaction, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,968 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the transaction, the chief executive officer directly owned 42,351 shares of the company's stock, valued at $12,455,852.61. This trade represents a 10.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock valued at $9,993,789 in the last three months. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.